Company news
Bavarian Nordic A/s (OMXCOP:BAVA) news
Bavarian Nordic A/s news releases on 6ix. Latest, Oct 5, 2026: Bavarian Nordic A/S : - Transactions in Connection with Share Buy-Back Program
Press releases & updates
Bavarian Nordic A/S : - Transactions in Connection with Share Buy-Back Program
October 5, 2026
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
October 5, 2026
Bavarian Nordic – Notification of Holding of Treasury Shares
September 22, 2026
Tarja Stenvall Appointed Chief Executive Officer of Bavarian Nordic
September 17, 2026
Bavarian Nordic Launches First Tranche of New Share Buy-Back Program
September 1, 2026
Bavarian Nordic Reports Strong First Half 2026 Results
August 21, 2026
Bavarian Nordic to Launch New Share Buy-back Program of up to DKK 750 Million
August 21, 2026
Bavarian Nordic Upgrades its Full-Year 2026 Financial Guidance
August 21, 2026
Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years
August 7, 2026
Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil
July 13, 2026
Bavarian Nordic A/S : - Completion of Share Buy-Back Program
July 13, 2026
Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine
June 29, 2026
Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine
June 9, 2026
Bavarian Nordic Announces Interim Results for the First Three Months of 2026
May 13, 2026
Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox Vaccines
May 11, 2026
Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S
April 21, 2026
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
April 20, 2026
Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine
April 16, 2026
Bavarian Nordic A/S : - Transactions in Connection with Share Buy-Back Program
April 13, 2026
Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years
March 27, 2026
Bavarian Nordic A/S – Notice Convening Annual General Meeting
March 24, 2026
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
March 12, 2026
Bavarian Nordic Launches Next Tranche of Share Buy-Back Program
March 12, 2026
Bavarian Nordic Publishes Annual Report 2025
March 12, 2026
Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement
March 11, 2026
Paul Chaplin Steps Down as CEO of Bavarian Nordic
March 2, 2026
Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada
February 18, 2026
Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026
February 12, 2026
Bavarian Nordic – Completion of Share Buy-Back Program
February 9, 2026
Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil
January 23, 2026
Bavarian Nordic Launches Planned Share Buy-Back Program
January 7, 2026
Bavarian Nordic Establishes Long-term Incentive Program for Members of Executive Management and Selected Employees
December 18, 2025
Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic
December 17, 2025
Bavarian Nordic to Launch Share Buy-back Program of up to DKK 500 Million
December 2, 2025
Bavarian Nordic to Host a Shareholder Information Meeting on December 11, 2025 in Copenhagen
November 26, 2025
Bavarian Nordic Announces Interim Results for the First Nine Months of 2025
November 14, 2025
Bavarian Nordic Announces Changes to the Board of Directors
November 13, 2025
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
November 10, 2025
Consortium consisting of Nordic Capital and Permira announces preliminary result of the takeover offer to shareholders of Bavarian Nordic and that the Offer is withdrawn and will not be completed
November 6, 2025
Bavarian Nordic Provides Clarification on the HERA Framework Agreement and the Public Preparedness Business
November 1, 2025
Bavarian Nordic shareholders are reminded of expiry of the offer period regarding the takeover offer from consortium consisting of Nordic Capital and Permira
October 31, 2025
Bavarian Nordic Awarded New Procurement Framework Contract by the European Commission to Strengthen Preparedness Against Smallpox and Mpox
October 31, 2025
Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines
October 28, 2025
Consortium consisting of Nordic Capital and Permira lowers the minimum acceptance condition to 66 2/3% in respect of the takeover offer to the shareholders of Bavarian Nordic
October 21, 2025
The Board of Directors maintains its recommendation in supplementary statement in respect of the improved takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira
October 16, 2025
Consortium consisting of Nordic Capital and Permira increases offer price and extends offer period until 5 November 2025 in respect of the takeover offer to the shareholders of Bavarian Nordic
October 15, 2025
Consortium consisting of Nordic Capital and Permira receives final regulatory approval in respect of its takeover offer to the shareholders of Bavarian Nordic
October 9, 2025
Bavarian Nordic Reports Positive Topline Data for Mpox/Smallpox Vaccine in Pediatric Population
October 7, 2025
Consortium consisting of Nordic Capital and Permira extends offer period until 14 October 2025 and provides update on regulatory approvals in respect of the takeover offer to the shareholders of Bavarian Nordic
September 29, 2025
Societe Generale: shares & voting rights as of 31 August 2025
September 9, 2025